GeoMx DSP analysis of tumor and stromal compartments in pre-treatment NSCLC samples
Immune checkpoint blockers have transformed the therapeutic landscape of oncology. In particular, therapies targeting the PD-1/PD-L1 axis have demonstrated major anti-tumor activity and are now approved across several solid tumors, including non-small cell lung cancer. However, most patients treated with PD-1 or PD-L1 inhibitors do not derive clinical benefit. There is therefore a critical need […]